<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Psilocybin &amp; MDMA-Assisted Therapy — Open Synthesis</title>
  <meta name="description" content="Comprehensive literature review on clinical trial evidence for psilocybin therapy for depression and MDMA-assisted therapy for PTSD.">
  <meta property="og:title" content="Psilocybin & MDMA-Assisted Therapy — Open Synthesis">
  <meta property="og:description" content="Multi-section synthesis of phase II/III trial results, effect sizes, and regulatory status.">
  <meta property="og:url" content="https://opensynthesis.dev/case-study-psychedelic-therapy.html">
  <meta property="og:type" content="article">
  <link rel="icon" type="image/png" href="favicon.png">
  <link rel="stylesheet" href="style.css">
</head>
<body>

  <nav class="case-study-nav">
    <div class="container">
      <a href="/" class="nav-home">Open Synthesis</a>
      <span class="nav-sep">/</span>
      <span class="nav-current">Case Studies</span>
    </div>
  </nav>

  <article class="case-study-article">
    <div class="container">

      <header class="article-header">
        <div class="case-study-tag">psychopharmacology</div>
        <h1>Psilocybin &amp; MDMA-Assisted Therapy</h1>
        <p class="article-meta">
          <span>Model: <a href="https://huggingface.co/opensynthesis/Qwen3-14B-heretic">Qwen3-14B-heretic</a></span>
          <span>Sources: Semantic Scholar, PubMed</span>
          <span>Date: 2026-02-21</span>
          <span>Pipeline: Multi-section synthesis</span>
        </p>
        <p class="article-query">"What is the current clinical trial evidence for psilocybin therapy for depression and MDMA-assisted therapy for PTSD? Summarize the phase II/III trial results, effect sizes, and regulatory status."</p>
      </header>

      <section class="article-section">
        <h2>Pharmacological Mechanisms and Therapeutic Rationale</h2>
        <p>Psilocybin and MDMA represent two pharmacologically distinct classes of psychoactive compounds that have emerged as leading candidates in a broader renaissance of psychedelic-assisted psychotherapy.</p>
        <p><strong>Psilocybin</strong> (4-phosphoryloxy-N,N-dimethyltryptamine) is a prodrug rapidly dephosphorylated to psilocin, which acts primarily as an agonist at serotonin 5-HT2A receptors [SOURCE 1]. At the neural systems level, psilocybin disrupts the default mode network (DMN), increases functional connectivity between normally uncommunicative brain regions, and is hypothesized to create a window of enhanced neuroplasticity during which psychotherapy can facilitate lasting cognitive and emotional restructuring [SOURCE 1].</p>
        <p><strong>MDMA</strong> (3,4-methylenedioxymethamphetamine) reverses monoamine transporter function, producing massive release of serotonin, dopamine, and norepinephrine, and stimulates oxytocin release [SOURCE 2]. The subjective effects — enhanced empathy, reduced fear and defensiveness — enable patients to engage with traumatic memories without being overwhelmed, facilitating deeper trauma processing than psychotherapy alone.</p>
        <p>Both compounds are administered in a small number of sessions (1–3 for psilocybin, 2–3 for MDMA) within a structured psychotherapeutic framework including preparatory sessions, the 6–8 hour dosing session with therapist support, and integration sessions [SOURCE 6]. This model represents a fundamentally different paradigm from maintenance pharmacotherapy.</p>
      </section>

      <section class="article-section">
        <h2>Psilocybin for Depression: Phase II and III Trial Evidence</h2>
        <p>A systematic review and meta-analysis of seven RCTs involving 522 participants found that psilocybin-assisted therapy produced a large and significant antidepressant effect, exceeding those typically observed with conventional antidepressants (SMD ≈ 0.30–0.40) [SOURCE 6]. Greater efficacy was observed with bodyweight-adjusted doses and extended preparation, dosing, and integration sessions alongside non-manualized psychotherapy.</p>
        <p>Early comparative studies suggest psilocybin may be superior to escitalopram for MDD [SOURCE 5]. In a head-to-head RCT, secondary outcomes consistently favored psilocybin, including response rates, remission rates, and measures of well-being. The rapid onset — hours rather than weeks — makes psilocybin notable for populations requiring urgent relief, such as head and neck cancer patients post-surgery [SOURCE 5].</p>
        <p>Treatment-resistant depression (TRD) represents a particularly important target. Early open-label studies showed marked improvements persisting for weeks to months after one or two sessions. Subsequent RCTs confirmed clinically meaningful effects, though magnitude has varied across studies [SOURCE 6].</p>
        <p>The durability profile compares favorably with conventional antidepressants, which require daily maintenance dosing and produce relapse upon discontinuation. Some patients do relapse after psilocybin therapy, and optimal retreatment schedules remain unestablished [SOURCE 6].</p>
      </section>

      <section class="article-section">
        <h2>MDMA-Assisted Therapy for PTSD: Phase II and III Trial Evidence</h2>
        <p>Phase II trials revealed that 54% of participants receiving full-dose MDMA (75–125 mg) no longer met PTSD diagnostic criteria after two sessions, compared to 23% in the control group [SOURCE 2]. Participants had chronic, treatment-resistant PTSD.</p>
        <p>Phase III trials confirmed and extended these findings: 67% of participants no longer met PTSD criteria after three sessions, with effects stable at one year (67%) and nearly four years (74%) [SOURCE 2].</p>
        <p>A pivotal phase III RCT (NCT03537014) reported mean CAPS-5 score changes of -24.4 (MDMA) vs. -13.9 (placebo), P < 0.0001, d = 0.91 [SOURCE 9]. This substantially exceeds FDA-approved PTSD pharmacotherapies (d = 0.30–0.50). Functional impairment also improved: SDS mean change of -3.3 (MDMA) vs. -2.1 (placebo), P = 0.03, d = 0.4 [SOURCE 18].</p>
        <p>Results were consistent across diverse populations, including participants with comorbid dissociation, depression, and substance use disorders [SOURCE 9]. A meta-analysis confirmed an overall SMD of -0.85, with NNT of approximately 3–4 [SOURCE 11].</p>
      </section>

      <section class="article-section">
        <h2>Effect Sizes in Comparative Context</h2>
        <p>For <strong>depression</strong>, conventional antidepressants produce d = 0.30–0.40 vs. placebo. Psilocybin-assisted therapy has shown effect sizes exceeding these by a factor of two or more [SOURCE 15].</p>
        <p>For <strong>PTSD</strong>, sertraline and paroxetine produce d = 0.30–0.50. MDMA-assisted therapy's d = 0.91 substantially exceeds these benchmarks and is comparable to or exceeds gold-standard psychotherapies (prolonged exposure, cognitive processing therapy: d = 0.70–1.00) [SOURCE 9].</p>
        <p>Important caveats: effect sizes may be inflated by small sample sizes, functional unblinding, participant expectancy, and enhanced therapeutic contact [SOURCE 15]. These factors do not invalidate the findings but suggest true effect sizes may be somewhat smaller than point estimates.</p>
      </section>

      <section class="article-section">
        <h2>Regulatory Status and FDA Review</h2>
        <p><strong>MDMA</strong> received FDA breakthrough therapy designation in 2017. The FDA Advisory Committee voted against recommending approval in 2024, citing concerns about blinding adequacy, potential bias from the therapeutic relationship, and incomplete adverse event reporting [SOURCE 3]. Additional trials may be required.</p>
        <p><strong>Psilocybin</strong> received FDA breakthrough therapy designation for TRD (2018) and MDD (2019). Phase III trials are ongoing. Oregon legalized regulated psilocybin therapy in 2020 (services began 2023), Colorado followed in 2022, and Australia rescheduled psilocybin for therapeutic use in 2023. Hawaii's Senate Bill 738 aimed to remove psilocybin from the state's Schedule I list [SOURCE 2].</p>
        <p>Both compounds remain Schedule I under US federal law. Breakthrough therapy designation creates a pathway for approval despite this status, but rescheduling may be necessary for widespread implementation.</p>
      </section>

      <section class="article-section">
        <h2>Safety, Tolerability, and Adverse Events</h2>
        <p><strong>Psilocybin:</strong> Common adverse events include transient anxiety, nausea, headache, and elevated blood pressure. Serious adverse events are rare. The primary concern is psychologically challenging experiences, managed through therapist support. Psilocybin has low physiological toxicity and does not produce physical dependence [SOURCE 6]. A specific concern in bipolar depression is affective switching [SOURCE 10].</p>
        <p><strong>MDMA:</strong> Common adverse events include bruxism, nausea, decreased appetite, and insomnia. Cardiovascular effects (increased heart rate, blood pressure, temperature) require monitoring [SOURCE 9]. The primary safety concern is potential serotonergic neurotoxicity from preclinical studies, though clinical trial participants have not shown significant cognitive impairment or structural brain changes [SOURCE 3].</p>
        <p>Functional unblinding is a pervasive challenge for both compounds, as participants can typically distinguish active drug from placebo [SOURCE 15]. Active placebo comparators partially address but do not fully resolve this issue.</p>
      </section>

      <section class="article-section">
        <h2>Methodological Limitations and Evidence Gaps</h2>
        <ul>
          <li><strong>Sample sizes:</strong> Most trials include fewer than 200 participants, increasing risk of inflated estimates [SOURCE 15].</li>
          <li><strong>Blinding:</strong> True double-blinding is extremely difficult with psychoactive compounds [SOURCE 15].</li>
          <li><strong>Therapist effects:</strong> Most trials use small numbers of highly trained, enthusiastic therapists, raising generalizability questions [SOURCE 3].</li>
          <li><strong>Diversity:</strong> Participants have been disproportionately white, educated, and psychedelic-experienced [SOURCE 9].</li>
          <li><strong>Long-term outcomes:</strong> Optimal dosing schedules, retreatment protocols, and long-term safety remain insufficiently characterized.</li>
          <li><strong>Other conditions:</strong> Evidence for psilocybin in bipolar depression remains preliminary with safety concerns [SOURCE 10].</li>
        </ul>
      </section>

      <section class="article-section article-section-last">
        <h2>Falsifiability Criteria</h2>
        <p>Evidence that would contradict or revise this synthesis:</p>
        <ul>
          <li>Larger phase III trials failing to replicate the observed effect sizes</li>
          <li>Demonstration that functional unblinding fully accounts for treatment effects</li>
          <li>Emergence of significant long-term neurotoxicity or cognitive impairment in MDMA participants</li>
          <li>Evidence that psilocybin's therapeutic effects are entirely attributable to the psychotherapeutic context</li>
          <li>Clinically significant harm in specific populations at rates altering the safety profile</li>
        </ul>
      </section>

      <div class="article-footer">
        <a href="https://github.com/opensynthesislabs/open-synthesis/blob/main/case_studies/psychedelic_therapy.md" class="btn btn-secondary">View on GitHub</a>
        <a href="/" class="btn btn-secondary">Back to Home</a>
      </div>

    </div>
  </article>

  <footer>
    <div class="container">
      <div class="footer-links">
        <a href="https://github.com/opensynthesislabs/open-synthesis">GitHub</a>
        <span>&middot;</span>
        <a href="https://huggingface.co/opensynthesis/Qwen3-14B-heretic">HuggingFace</a>
        <span>&middot;</span>
        <a href="https://github.com/opensynthesislabs/open-synthesis/blob/main/WHITEPAPER.md">Whitepaper</a>
        <span>&middot;</span>
        <a href="https://github.com/opensynthesislabs/open-synthesis/blob/main/LICENSE">MIT License</a>
      </div>
    </div>
  </footer>

</body>
</html>
